2025-01-31T12:00:00
KELIM cited in the recent ASCO guidelines for neo-adjuvant chemotherapy !
The updated ASCO guidelines about the management of patients treated with neo-adjuvant chemotherapy have just been published in https://ascopubs.org/doi/10.1200/JCO-24-02589 KELIM is cited as an indicator of the neo-adjuvant chemotherapy efficacy !
2025-01-06T12:00:00
Your CA-125 KELIM can now be calculated in Chinese Mandarin langage ! 您的 CA-125 KELIM 现在可以用中文普通话计算！
Happy New Year 2025! The Biomarker-Kinetics team is pleased to share with you the new Mandarin Chinese version of the website. All you need to do is click the “ZH” button in the upper left corner. 2025 年新年快乐！ 生物标记-动力学团队很高兴与大家分享网站的全新中文普通话版本。您只需点击左上角的 “ZH ”按钮即可。
2024-09-28T12:00:00
KELIM presented at the international PSOGI ISSP1 ESGO congress
The first consensual meeting about Peritoneal surface malignancies involving PSOGI, ISSP and ESGO was organized in Lyon, France from 26 to 28th September 2024. A big success for KELIM across several countries on the globe !
2024-08-23T12:00:00
SALVOVAR phase III trial: Activated in France and Japan => Already 5 patients enrolled !
SALVOVAR is a phase III trial meant to show that densification of the chemotherapy with the weekly dose-dense paclitaxel in patients presenting with an unfavorable KELIM score < 1.0 and a disease not amenable to complete interval debulking surgery could improve their prognosis. For more details : https://salvovar-cms-uploads.s3.fr-par.scw.cloud/e2898237-e03b-4554-85e8-a2440af3e56d.mp4